Anbio Biotechnology Class A Ordinary Shares logo

Anbio Biotechnology Class A Ordinary Shares(NNNN)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$3.82
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for NNNN

11/13/2026: NNNN (1-star) is currently NOT-A-BUY. Pass it for now.

Anbio Biotechnology is a recently public, small-cap medical device firm specializing in decentralized in vitro diagnostic (IVD) solutions. Its primary strengths include a diverse technology portfolio—such as PCR and immunoassay platforms—and an agile approach to rapid testing. The company’s growth story hinges on its ability to expand its international distribution network and penetrate professional clinical markets. However, investors face notable risks, including intense competition from global healthcare giants, high stock price volatility, and the execution challenges inherent in scaling a young biotech firm. Anbio is likely best suited for growth-oriented investors with a high risk tolerance who are monitoring the firm’s ability to secure long-term clinical contracts.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorMixed fitThe company offers high-growth potential in the IVD space but carries significant execution and competitive risks.
Momentum investorStrong fit while signal remains positiveThe stock's high volatility can attract momentum traders when positive technical or news-driven signals emerge.
Value investorWeak fitAs an early-stage biotech firm, valuation metrics are difficult to establish and may not conform to traditional value standards.
Dividend investorWeak fitThe company does not pay dividends and focuses entirely on growth and commercial scaling.
Low-risk investorWeak fitThe stock's high volatility and small-cap status make it unsuitable for conservative, risk-averse portfolios.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighThe stock experiences significant price swings typical of small-cap emerging biotechnology companies.
Valuation riskMedium / highEstablishing a fair valuation is challenging due to the company's limited financial track record.
Competition risk (Large-scale IVD giants)HighThe company faces intense competition from well-funded, global market leaders like Abbott and Roche.
Business qualityMediumWhile the company has a strong technology focus, its market franchise is still in the early stages of development.
Dividend incomeLow / noneThe company is in a growth phase and does not offer income to shareholders.
Execution riskMedium / highSuccess depends on the company's ability to effectively scale distribution and achieve regulatory milestones globally.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 167.66M USD
Price to earnings Ratio 25.47
1Y Target Price -
Price to earnings Ratio 25.47
1Y Target Price -
Volume (30-day avg) 51.1K shares
Beta -
52 Weeks Range 3.09 - 44.73
Updated Date 11/14/2026
52 Weeks Range 3.09 - 44.73
Updated Date 11/14/2026
Dividends yield (FY) -
Basic EPS (TTM) 0.15

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Medical Instruments & Supplies

BUY participation
60.0%
Active BUY / eligible
3 / 5
30-Day BUY Count Change
+1

Eligible universe: 5 stocks.

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Steep Decline
PRICE PATH

Steep Decline

The stock price has dropped sharply with strong downward pressure.

Highly Choppy
PRICE STABILITY

Highly Choppy

The stock has experienced frequent, large price swings that make its near-term movement less predictable.

Analysis of Past Performance

Type Stock
Historic Profit 139.32%
Avg. Invested days 23
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
Stock Returns Performance Upturn Returns Performance icon 5.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
NNNN receives a 3-star rating, supported by solid company fundamentals. The rating is constrained by soft analyst coverage, and weak price momentum.

Company Fundamentals

★★★★★
NNNN has solid overall fundamentals (4 stars), with solid financial health, solid growth momentum, and moderate ownership. In FY2025 versus FY2024, strong earnings growth (+169.9%) and strong profitability (net margin 74.1%) are partially offset by weak cash generation (FCF margin -77.9%), moderate revenue growth (+5.6%), modest insider ownership of 4.78%.

Financial Health Rating

★★★★★
NNNN's financial health is supported by strong profitability, including gross margin of 87.2% and operating margin of 66.7%. Cash strength is moderate (3 stars), which helps explain the 4-star overall score.

Growth Momentum Score

★★★★★
Earnings growth is NNNN's strongest growth driver at +169.9% FY2025 versus FY2024 (strong, 5 stars). By comparison, while revenue growth (+5.6%, moderate) and free-cash-flow growth (-423.9%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 5.0% (soft) and 90.4% of outstanding shares are publicly tradable (strong). Insider ownership of 4.78% provides only moderate management-shareholder alignment.

Top 5 Institutional Investors

Geode Capital Management, LLC 0.06%
Bank of America Corp 0.03%
BNP Paribas Arbitrage, SA 0.03%
Marshall Wace Asset Management Ltd 0.03%
Morgan Stanley - Brokerage Accounts 0.02%

Unit Economics (Per $1K Revenue)

★★★★★
NNNN generates approximately $872 of gross profit, $667 of operating income, and $-779 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Weak margins and weak cash conversion support a 3-star rating, while capital efficiency is strong.

Economic Dimensions

★★★★★
Effective Tax Rate: 0.00%

Quantitative Style Profile

★★★★★
NNNN has a high-quality, liquid, relatively low-volatility profile. Weak momentum is the primary drawback, while soft valuation.

Style Classification

Quality Focused

Quality TiltLow VolatilitySmall / Mid Cap RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
In Vitro Diagnostics (IVD)Sales of rapid test kits, molecular PCR systems, and immunoassay platforms.Revenue comes primarily from selling diagnostic testing hardware and recurring kit consumables to hospitals and clinics.
GeographySales across Europe, Asia-Pacific, North America, and Africa.The company relies on a globally diversified sales strategy to mitigate regional market risks.

Analyzing Revenue: Products, Geography and Growth

Revenue by Geography

Geography revenue - Year on Year

Valuation

Trailing PE 25.47
Forward PE -
Enterprise Value 154.89M
Price to Sales(TTM) 19.39
Enterprise Value 154.89M
Price to Sales(TTM) 19.39
Enterprise Value to Revenue 17.91
Enterprise Value to EBITDA 26.85
Shares Outstanding 43.89M
Shares Floating 39.69M
Shares Outstanding 43.89M
Shares Floating 39.69M
Percent Insiders 4.78
Percent Institutions 5.01

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.